全文获取类型
收费全文 | 118987篇 |
免费 | 7212篇 |
国内免费 | 1581篇 |
专业分类
耳鼻咽喉 | 1607篇 |
儿科学 | 2989篇 |
妇产科学 | 4137篇 |
基础医学 | 18319篇 |
口腔科学 | 3645篇 |
临床医学 | 9267篇 |
内科学 | 21622篇 |
皮肤病学 | 2438篇 |
神经病学 | 8003篇 |
特种医学 | 4081篇 |
外国民族医学 | 3篇 |
外科学 | 16842篇 |
综合类 | 5216篇 |
一般理论 | 34篇 |
预防医学 | 8698篇 |
眼科学 | 2836篇 |
药学 | 10243篇 |
中国医学 | 819篇 |
肿瘤学 | 6981篇 |
出版年
2021年 | 910篇 |
2019年 | 1086篇 |
2018年 | 1652篇 |
2017年 | 1194篇 |
2016年 | 1243篇 |
2015年 | 1483篇 |
2014年 | 1935篇 |
2013年 | 2507篇 |
2012年 | 3620篇 |
2011年 | 3875篇 |
2010年 | 2315篇 |
2009年 | 2079篇 |
2008年 | 3433篇 |
2007年 | 3674篇 |
2006年 | 3632篇 |
2005年 | 3186篇 |
2004年 | 3005篇 |
2003年 | 2792篇 |
2002年 | 2644篇 |
2001年 | 6736篇 |
2000年 | 6931篇 |
1999年 | 5691篇 |
1998年 | 1780篇 |
1997年 | 1340篇 |
1996年 | 889篇 |
1995年 | 863篇 |
1992年 | 3730篇 |
1991年 | 3813篇 |
1990年 | 3552篇 |
1989年 | 3560篇 |
1988年 | 3438篇 |
1987年 | 3289篇 |
1986年 | 3098篇 |
1985年 | 2974篇 |
1984年 | 2052篇 |
1983年 | 1793篇 |
1982年 | 988篇 |
1979年 | 1910篇 |
1978年 | 1185篇 |
1977年 | 985篇 |
1976年 | 918篇 |
1975年 | 1190篇 |
1974年 | 1356篇 |
1973年 | 1414篇 |
1972年 | 1356篇 |
1971年 | 1246篇 |
1970年 | 1135篇 |
1969年 | 1113篇 |
1968年 | 1025篇 |
1967年 | 896篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
31.
V. Papp A. Iljicsov C. Rajda M. Magyari N. Koch‐Henriksen T. Petersen G. Jakab I. Deme F. Nagy P. Imre Z. Lohner K. Kovcs A. J. Birks . Kves G. Rum Z. Nagy L. Kernyi L. Vcsei K. Bencsik Z. Jobbgy P. Diszeghy L. Horvth G. Galntai J. Kasza G. Molnr M. Sim M. Stori C. Rzsa P. cs T. Berki G. Lovas S. Komoly Z. Illes 《European journal of neurology》2020,27(2):308-317
32.
ABSTRACTIntroduction: Skin conditions are common and highly varied in their etiology; therefore, a diverse array of therapeutics are utilized. Drug safety studies in dermatology can be challenging as there are over 3000 diagnoses to consider. As a result, dermatologists rely on data from multiple sources including clinical trials and real-world evidence.Areas covered: In this review, we cover the main sources of safety data available, their strengths and weaknesses and how dermatologists should utilize such data. We use real-world examples of the different types of adverse events reported and how they are best captured by either randomized controlled trials or post-marketing pharmacovigilance methods. With multiple new therapies in dermatology, such as dupilumab for atopic dermatitis and janus-kinase inhibitors for alopecia areata the specialty is awash with evolving high-level evidence for their use. It is important to understand the optimal way to assess safety from trials but also appreciate the need for ongoing capture of safety data in clinical practice.Expert opinion: In dermatology, there is a plethora of conditions to treat and clinical trials, post-marketing surveillance, such as drug registries and spontaneous reporting, all enable dermatologists to gain a more comprehensive understanding of the safety profiles of drugs being used. 相似文献
33.
Zöllner Johann Philipp Paule Esther Wagner Marlies Freiman Thomas M. Rosenow Felix Strzelczyk Adam 《Zeitschrift für Epileptologie》2020,33(1):15-21
Clinical Epileptology - Temporale Enzephalozelen sind bisher nur in wenigen Fällen als Ursache von symptomatischen Epilepsien beschrieben worden. Zunehmende Beschreibungen in Fallserien weisen... 相似文献
34.
35.
36.
37.
38.
Emma Carpenter Bethany G. Everett Madelyne Z. Greene Sadia Haider C. Emily Hendrick Jenny A. Higgins 《Social work in health care》2020,59(3):180-198
ABSTRACTSexual minority women (SMW) face both increased risk for unintended pregnancy and barriers to achieving wanted pregnancy, but little research investigates SMW’s pregnancy desires. To fill this gap, we conducted five focus groups and 11 in-depth interviews with 20-30-year-old SMW in three US cities. Findings highlight that the heteronormative pregnancy planning paradigm lacks salience for SMW. While some SMW clearly wish to avoid pregnancy, many others are unsure, and factors influencing this uncertainty include relationship context, anticipating logistical barriers, and discord between queer identity and pregnancy. 相似文献
39.
Hermann Einsele MD Hossein Borghaei DO Robert Z. Orlowski MD Marion Subklewe MD Gail J. Roboz MD Gerhard Zugmaier MD Peter Kufer MD Karim Iskander MD Hagop M. Kantarjian MD 《Cancer》2020,126(14):3192-3201
Immuno-oncology therapies engage the immune system to treat cancer. BiTE (bispecific T-cell engager) technology is a targeted immuno-oncology platform that connects patients' own T cells to malignant cells. The modular nature of BiTE technology facilitates the generation of molecules against tumor-specific antigens, allowing off-the-shelf immuno-oncotherapy. Blinatumomab was the first approved canonical BiTE molecule and targets CD19 surface antigens on B cells, making blinatumomab largely independent of genetic alterations or intracellular escape mechanisms. Additional BiTE molecules in development target other hematologic malignancies (eg, multiple myeloma, acute myeloid leukemia, and B-cell non-Hodgkin lymphoma) and solid tumors (eg, prostate cancer, glioblastoma, gastric cancer, and small-cell lung cancer). BiTE molecules with an extended half-life relative to the canonical BiTE molecules are also being developed. Advances in immuno-oncology made with BiTE technology could substantially improve the treatment of hematologic and solid tumors and offer enhanced activity in combination with other treatments. 相似文献
40.